PP2A hyperphosphorylation, as well as upregulation of the endogenous PP2A inhibitors such as SET, has been reported as main molecular mechanisms of PP2A inhibition in many tumors including breast cancer. This evidence concerns the gene PTPA and breast carcinoma.